Condition 1: Pruritus. Condition 2: End Stage Renal Disease. Other pruritus Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: The treatment group consists of 30 patients receiving 1200 mg of omega-3 fatty acids daily for 3 months. Intervention 2: The control group consisted of 30 patients who received 1200 mg
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria:Age over 18 years ; Beginning hemodialysis for at least 3 months and three times per week ; Ability to understand and sign consent form ; Use of biocompatible dialysis membrane. Properly functioning arteriovenous fistula or catheter function; Dialysis adequacy above 1.2.
Exclusion criteria
Exclusion criteria: Exclusion criteria : Other causes of itching, except kidney failure ; Pregnancy ; The presence of any chronic, active, uncontrolled or severe chronic inflammatory disease (autoimmune diseases, connective tissue disease, malignancy, HIV, liver disease and pulmonary disease) ; presence of chronic infection or acute infection in the last month ; Hemoglobin less than 10 g / dL ; Co-presence in another trial ; Medical history (such as heart attack ) or surgical in the last 3 months ; Symptoms of malabsorption ; Bleeding disorders ( Includes coagulopathies) or high risk of bleeding ; Change in diet in the last 1 month; Consumption of Omega-3 or any supplement containing omega-3 in the last 3 months. ; Intolerance or susceptibility to drug ; Receiving drugs that have an effect on inflammatory factors (corticosteroids or other immunosuppressive drugs, non-steroidal anti-inflammatory drugs, contraceptives, pentoxifylline) in the last 6 weeks; Concomitant use of methyl dopa, cimetidine and serotonergic drugs such as triptans, tramadol, tryptophan and linzolide ; Use of warfarin ; Abuse of alcohol and other substances that cause dependence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pruritus score. Timepoint: Before intervention. Six weeks after the intervention. At the end of the intervention. Method of measurement: Standard questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Hemiglobincyanide(HiCN) method.;Serum Creatinine level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Jaffe method.;Serum phosohorus level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Colorimetric method.;Serum Calcium Level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Colorimetric method.;Blood Urea nitrogen. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Enzymatic method.;Cholesterol level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Enzymaticl method.;Triglyceride level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Enzymatic method.;Serum Ferritin level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: ELISA Kit.;Serum Iron level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Colorimetric method.;Parathyroid Hormone level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Immunoassay (Analytical methods ).;C_Reactive protein level. Timepoint: Immediately before the intervention, in the second month of intervention, after the intervention. Method of measurement: Latex agglutination method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfshin Gharekhani
Tabriz University of Medical Sciences
Outcome results
None listed